Prospectively, given the pathogenetic mechanism underlying obesity-related genes SIM1 and SEMA3-PLXNA, the therapeutic role of setmelanotide can be hypothesized, and is currently being evaluated (ClinicalTrials.gov ID: NCT04963231, NCT05093634). The gene discussed is SIM1; the disease is obesity due to melanocortin 4 receptor deficiency.